Vertex Pharma stock pre-market at EUR 448.15 before the Xetra open

Published on 10/20/2026 at 07:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vertex Pharma develops medicines, with cystic fibrosis therapies at the center of its business. At Lang & Schwarz, the stock trades pre-market at EUR 448.15 on October 20, 2026.

Business and market context

Vertex Pharma develops and markets medicines, including therapies for cystic fibrosis.
Vertex Pharmaceuticals trades on the Nasdaq in the United States.
Vertex Pharma stock trades pre-market at EUR 448.15 at 7:46 a.m. CEST at Lang & Schwarz on October 20, 2026.

Extreme Nahaufnahme von Pharmakapseln und Tabletten auf glänzender Glasoberfläche — Vertex Pharma US92532F1003 zeigt eine Makroaufnahme von Pharma-Kapseln und Tabletten mit feinen Wassertropfen, Illustration mit AI erstellt.

Vertex Pharma develops and markets prescription medicines, with cystic fibrosis treatments forming the center of its commercial business. The stock trades pre-market at EUR 448.15 at 7:46 a.m. CEST at Lang & Schwarz on October 20, 2026.

How Vertex Pharma operates

The company sells medicines through specialty pharmacies and distributors in the United States, while international sales are handled through specialty distributors, retail chains, hospitals and clinics.

Pre-market indication

Vertex Pharma is quoted at Lang & Schwarz before the Xetra open. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Vertex Pharma stock.